Published on September 9, 2009 at 6:47 AM
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its INSPIRE Phase I/IIa study of HIV-infected patients with low CD4 T cell counts treated with a three injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), will be presented during an oral late breaker session at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held September 12-15, 2009, in San Francisco, CA.
Yves Levy, MD, PHD, Scientific Director of the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) Vaccine Program, Service d'Immunologie Clinique, Hôpital Henri Mondor, Créteil, France and Inserm, Principle Investigator and Co-Chair of the INSPIRE study will present the interim data analysis from the clinical trial.
The presentation details are as follows:
Session: 143-HIV, Monday, September 14, 2009, 8:30 AM -11:00 AM
Session Type: Slide Session
Location: Room 301
Abstract Number: H-1230a
Presentation Time: Monday, September 14, 2009, 10:15 AM -10:30 AM
Presentation Title: Effects of r-hIL-7 on T Cell Recovery and Thymic Output in HIV-infected Patients Receiving Antiretroviral Therapy. Interim Analysis of a Phase I/IIa Multicenter Study
http://www.cytheris.com/
66d10d34-0f37-485d-8c3a-62b26e056c2c|0|.0
Posted in: Drug Trial News
Tags: Antiretroviral, Bone, Bone Marrow, Cancer, Cell, Chemotherapy, Hepatitis A, Hepatitis E, Interleukin-6, Oncology, Radiotherapy, Vaccine